Page last updated: 2024-09-03

mk 0663 and Breathlessness

mk 0663 has been researched along with Breathlessness in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ahmed, I; El Gaafary, M; El Miedany, Y; Youssef, S	1

Trials

1 trial(s) available for mk 0663 and Breathlessness

Article	Year
Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 97, Issue:1 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provocation Tests; Cross Reactions; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Dyspnea; Etoricoxib; Female; Forced Expiratory Volume; Humans; Male; Peak Expiratory Flow Rate; Pyridines; Rheumatic Diseases; Single-Blind Method; Sulfones	2006

Article

Year

Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 97, Issue:1

Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provocation Tests; Cross Reactions; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Dyspnea; Etoricoxib; Female; Forced Expiratory Volume; Humans; Male; Peak Expiratory Flow Rate; Pyridines; Rheumatic Diseases; Single-Blind Method; Sulfones

2006